Survival impact of initial local therapy selection for men under 60 with high risk prostate cancer. Prostate cancer (PCa) in 696 hypogonadal men with and without long-term testosterone therapy (TTh): ...

Upgrade and downgrade rates from targeted biopsy to radical prostatectomy were not significantly different between patients whose MRI examinations were clinically interpreted using PI-RADS Version ...

Prostate specific antigen testing as disease surveillance and monitoring five years after definitive therapy for localized prostate cancer. Relative risk of HTN and major cardiovascular events ...

PI-RADS version 2.1 demonstrated improved detection of clinically significant prostate cancer in the transition zone. For detecting clinically significant prostate cancer (csPCa), prostate imaging ...

An artificial intelligence (AI) system was better at detecting clinically significant prostate cancer on MRI compared with radiologists, a noninferiority, confirmatory study showed. In a subset of 400 ...

Combining PSA density with prostate MRI findings improves the predictive performance of PI-RADS in men without a prior prostate cancer diagnosis. Combining PSA density (PSAD) with prostate magnetic ...

Innovative technology performs automatic segmentation and lesion detection in prostate MRI scans to assist in PI-RADS scoring for prostate cancer management TEL AVIV, Israel & SAN JOSE, ...

MRI of the prostate, combined with a blood test, can help determine if a prostate lesion is clinically significant cancer, new research suggests. A new meta-analysis by investigators from Brigham and ...

A recent Radiology journal study assesses the power of a fully automated deep learning (DL) model to produce deterministic outputs for identifying clinically significant prostate cancer (csPCa). Study ...